A statement released earlier today by Robert W. Baird about Coherus BioSciences (NASDAQ:CHRS) ups the target price to $40.00
- Updated: October 19, 2016
Stating a potential upside of 0.37%, Robert W. Baird bumped up the target of Coherus BioSciences (NASDAQ:CHRS) to $40.00
On 9/7/2016, Maxim Group reported on Coherus BioSciences (NASDAQ:CHRS) increased the target price from $0.00 to $43.00 that indicated a possible upside of 0.43%.
Yesterday Coherus BioSciences (NASDAQ:CHRS) traded 1.18% higher at $29.22. The company’s 50-day moving average is $29.09 and its 200-day moving average is $23.41. The last stock close price is up 24.84% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Volume of trade was down over the average, with 323,090 shares of CHRS changing hands under the typical 366,905
With a total market value of $0, Coherus BioSciences has with a one year low of $12.04 and a one year high of $31.98 .
Brief Synopsis About Coherus BioSciences (NASDAQ:CHRS)
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.